Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Roquefort Investments PLC ( (GB:ROQ) ) is now available.
Roquefort Therapeutics has agreed to acquire the exclusive worldwide licence to AO-252, a clinical-stage, orally administered, brain-penetrant small molecule inhibitor of TACC3 from Coiled Therapeutics Inc. The deal, valued at £31.875 million in shares, will transform the business into a clinical-stage oncology company with a portfolio including AO-252, now in a U.S. Phase I trial for advanced solid tumours, and an existing STAT-6 programme being evaluated for clinical development.
Alongside the acquisition, the company is raising £8.5 million via a conditional placing and subscription at 10 pence per share, with senior leaders participating and net proceeds of about £7.7 million earmarked to advance AO-252 through key clinical milestones in 2026–27 and provide working capital. Roquefort will cancel its Main Market listing, seek admission of its enlarged share capital to AIM, rebrand as Coiled Therapeutics plc, refresh its board, and position itself to tap strong pharma interest in precision oncology, particularly prostate and ovarian cancer therapies.
The most recent analyst rating on (GB:ROQ) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Roquefort Investments PLC stock, see the GB:ROQ Stock Forecast page.
Spark’s Take on GB:ROQ Stock
According to Spark, TipRanks’ AI Analyst, GB:ROQ is a Neutral.
The score is primarily held back by weak financial fundamentals (pre-commercial revenue volatility, ongoing losses and cash burn). Technical indicators also point to a sustained downtrend. Low leverage on the balance sheet provides some support, but the negative P/E and lack of dividend yield limit valuation appeal.
To see Spark’s full report on GB:ROQ stock, click here.
More about Roquefort Investments PLC
Roquefort Therapeutics plc is a biotech company focused on oncology, developing precision cancer therapies targeting novel mechanisms such as TACC3 and STAT-6. The company is repositioning itself as a clinical-stage business with assets aimed at solid tumours, including ovarian and prostate cancers, and plans to operate under the new name Coiled Therapeutics plc on AIM.
Average Trading Volume: 1,025,206
Technical Sentiment Signal: Sell
Current Market Cap: £1.64M
For an in-depth examination of ROQ stock, go to TipRanks’ Overview page.